We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-6 of 6

Indian Supreme Court rules Novartis cancer drug change not patentable
  • Shook Hardy & Bacon LLP
  • India
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also

Indian pharma interests challenge U.S. allegations of discriminatory treatment
  • Shook Hardy & Bacon LLP
  • USA, India
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against

Drug companies and policymakers watch patent dispute before India’s high court
  • Shook Hardy & Bacon LLP
  • India
  • March 15 2012

According to a news source, the India Supreme Court will hear final arguments in March 2012 on whether the manufacturer of a drug that could not be patented in India because it was created before 1995 during a moratorium on the grant of patents to Western companies, may obtain a patent in that country for a newer form of the drug

House Subcommittee considers India’s pharmaceutical patent policies
  • Shook Hardy & Bacon LLP
  • India, USA
  • July 11 2013

During a recent hearing before the Subcommittee on Commerce, Manufacturing, and Trade of the House Energy & Commerce Committee, witnesses reportedly

Madeleine M. McDonough
  • Shook Hardy & Bacon LLP